ArticleSingapore medical journal2016
Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis.
Article in Singapore medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Vernal Keratoconjunctivitis: A Systematic Review.Clinical reviews in allergy & immunology · 2023Pooled it
- Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists.Indian journal of ophthalmology · 2023Article
- Treating refractory corneal hydrops in a male patient with vernal keratoconjunctivitis and mental retardation: a case report.BMC ophthalmology · 2022Article
- A comparative study between ciclosporine A eye drop (2%) and tacrolimus eye ointment (0.03%) in management of children with refractory vernal keratoconjunctivitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Efficacy and Safety of 0.1% Cyclosporine versus 2% Cyclosporine in the Treatment of Severe Vernal Keratoconjunctivitis in Children.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Understanding Vernal Keratoconjunctivitis: Beyond Allergic Mechanisms.Life (Basel, Switzerland) · 2021Review
- Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.The ocular surface · 2021Review
- Clinical Observation of Allergic Conjunctival Diseases with Portable and Recordable Slit-Lamp Device.Diagnostics (Basel, Switzerland) · 2021Article
- Article
- Therapeutic effects of Houttuynia eye drops combined with olopatadine hydrochloride eye drops on vernal keratoconjunctivitis.Experimental and therapeutic medicine · 2019Article
- Vernal keratoconjunctivitis.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- Biochemical and molecular alterations and potential clinical applications of biomarkers in keratoconus.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
- Approaches toward enhancing survival probability following deep anterior lamellar keratoplasty.Therapeutic advances in ophthalmologyReview
- Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhile corticosteroids are an effective choice of treatment for severe vernal keratoconjunctivitis (VKC), their long-term use is restricted due to side effects. This study was conducted to evaluate the efficacy and safety of topical cyclosporine A (CsA) 0.05% in the treatment of VKC.
methodsA total of 30 patients with VKC that was resistant to topical corticosteroids, antihistamines and mast cell stabilisers were treated with topical CsA 0.05%. Patients were evaluated at Weeks 4, 8 and 12 after the initiation of therapy. Symptoms and signs observed before and after treatment were recorded and scores were assigned. Scores for symptoms and signs, the need for topical corticosteroids and ocular side effects were evaluated.
resultsAt baseline, the median values of the symptom and sign scores were 10.0 (range 5.0-18.0) and 6.0 (range 2.0-13.0), respectively. At Week 4 of treatment with topical CsA 0.05%, the median values of the symptom and sign scores were 3.0 (range 0-14.0) and 3.0 (range 0-8.0), respectively. The reductions in the symptom and sign scores were statistically significant. The reduction in the need for corticosteroid was statistically significant by Week 12 of therapy. No significant side effects were reported.
conclusionTopical CsA 0.05%, which can help to reduce corticosteroid usage, is an effective and safe alternative for the treatment of resistant VKC. Further studies are needed to determine the optimal duration of therapy and possibility of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.